Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Clinical trial NCT05309213 · UNKNOWN
Trial details
- NCT number
- NCT05309213
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2025-04-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.